No Detail Found!

The Impact of IV Labetalol on Cardiotocographic Changes in Severe Preeclampsia

Author(s)
Samina Aliya Sabir Department of Obstetrics and Gynaecology, Lady Reading Hospital MTI,Peshawar,Pakistan
Farnaz Zahoor Department of Obstetrics and Gynaecology, Lady Reading Hospital MTI,Peshawar,Pakistan
Ghulam Abbas Department of Medicine, Khyber Teaching Hospital,Peshawar,Pakistan
Abstract
To evaluate the impact of intravenous (IV) labetalol on cardiotocographic (CTG) ndings in patients with severe preeclampsia and to determine its association, if any, with emergency caesarean section indications. Study Design: Descriptive case series. Place and Duration of the Study: Department of Obstetrics and Gynaecology, Lady Reading Hospital MTI, Peshawar, Pakistan, from August 2023 to January 2024. Methodology: Seventy-six pregnant women with severe preeclampsia (BP e160/110 mmHg) received IV labetalol for hypertension control, with continuous CTG monitoring for foetal well-being. Labetalol dosage, number of medicines administered, time to emergency caesarean, and CTG ndings were recorded. Emergency caesarean sections were performed based on obstetric indications such as non-reassuring CTG or foetal distress, not due to labetalol administration. Data were analysed using SPSS version 23, with p <0.05 considered statistically signi cant. Results: Out of the 76 patients, 68.4% (n = 52) had normal CTG ndings, while 31.6% (n = 24) showed abnormalities. No signi cant association was found between labetalol dosage and CTG outcomes (p = 0.558). The mean time to emergency caesarean section was 10.07 ± 2.74 minutes, re ecting the clinical urgency in cases with foetal compromise rather than a direct e ect of labetalol. Conclusion: While IV labetalol is already widely recommended in guidelines, this study adds value by evaluating its impact on realtime foetal monitoring through CTG in a local clinical context. IV labetalol e ectively controls blood pressure in severe preeclampsia without signi cantly a ecting CTG ndings, supporting its safety in managing maternal hypertension and foetal outcomes.
Publication Details
Page(s) 789-792
Published Journal: Journal of the College of Physicians and Surgeons Pakistan, Volume: 35, Issue: 06, Year: 2025

Request the full text from PASTIC

Keywords
Hypertension, Preeclampsia, Labetalol, Cardiotocography, Foetal monitoring
References
Awaludin A,Rahayu C,Daud NAA,Zakiyah N. .2022 .Antihypertensive medications for severe hypertension in pregnancy: A systematic review and meta-analysis. Healthc, 10(2) : 325.
Wasim T,Agha S,Saeed K,Riaz A .2020 .Oral nifedipine versus IV labetalol in severe preeclampsia: A randomized control trial. Pak J Med Sci, 10(6) : 1147-52.
Baqai SM,Rahim R,Ala H,Tarar SH,Waqar F,Yasmeen H .2022 .Society of obstetricians and gynaecologists Pakistan (SOGP) - Hypertensive disorders in pregnancy guidelines 2022. Pak Armed Forces Med J, 72(3) : 731-53.
Sridharan K,Sequeira RP .2018 .Drugs for treating severe hypertension in pregnancy: A network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol, 10(9) : 1906-16.
Ghi T,Eggebo TM,Lees C,Marlow N,Visser GH .2013 .ISUOG clinical standards committee. ISUOG practice guidelines: Use of Doppler ultrasonography in obstetrics. Ultrasound Obstet Gynecol, 10(2) : 233-9.
Magee LA,von Dadelszen P,Rey E,Ross S,Asztalos E,Murphy KE .2015 .Less-tight versus tight control of hypertension in pregnancy. N Engl J Med, 10(5) : 407-17.
Vigil-De Gracia P,Lasso M,Ruiz E,Vega-Malek JC,de Mena FT,Lopez JC .2006 .Severe hypertension in pregnancy: Hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol, 02(1-2) : 157-62.
Baggio MR,Martins WP,Calderon AC,Berezowski AT,Marcolin AC,Duarte G .2010 .Changes in foetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: A randomized controlled trial. Ultrasound Med Biol, 10(1) : 53-8.
Belfort MA,Saade GR,Moise KJ .1993 .The e ect of magnesium sulfate on maternal and foetal blood ow in pregnancyinduced hypertension. Acta Obstet Gynecol Scand, 10(7) : 526-30.
Magee LA,Abalos E,von Dadelszen P,Sibai B,Easterling T,Walkinshaw S. .2011 .How to manage hypertension in pregnancy e ectively. Br J Clin Pharmacol2011;, 04002(3) : 2125-401.
Nombur LI,Agida ET,Isah AY,Ekele BA .2014 .A comparison of hydralazine and labetalol in the management of severe preeclampsia. J Womens Health Care, 10(6) : 1000186-0420.
Cantarutti A,Porcu G,Locatelli A,Corrao G .2022 .Association between hypertensive medication during pregnancy and risk of several maternal and neonatal outcomes in women with chronic hypertension: A population-based study. Expert Rev Clin Pharmacol, 2072292(5) : 637-45.
0

Citations

0

Downloads

46

Views